 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Divis Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 3784.45, up 1.29% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.11% on the day, quoting at 19975.15. The Sensex is at 67131.77, up 0.01%. Divis Laboratories Ltd has gained around 1.44% in last one month. Meanwhile, Nifty Metal index of which Divis Laboratories Ltd is a constituent, has gained around 0.16% in last one month and is currently quoting at 15309.95, up 0.13% on the day. The volume in the stock stood at 5.29 lakh shares today, compared to the daily average of 4.36 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 3784, up 1.23%  on the day. Divis Laboratories Ltd is up 3.19% in last one year as compared to a 10.54% jump in NIFTY and a 20.27% jump in the Nifty Metal index.The PE of the stock is 67.81 based on TTM earnings ending June 23.

Divis Laboratories Ltd soars 1.29%, rises for third straight session

Motilal Oswal recommended Neutral rating on Divi’s Laboratories with a target price of Rs 3430 in its research report dated August 15, 2023.

Neutral Divi’s Laboratories; target of Rs 3430: Motilal Oswal

Prabhudas Lilladher recommended hold rating on Divi's Laboratories with a target price of Rs 3000 in its research report dated August 15, 2023.

Hold Divi's Laboratories; target of Rs 3000: Prabhudas Lilladher

Emerging $20 billion generics opportunity, cost leadership, existing capacity, excellent regulatory track record, operational efficiency and laser-sharp focus on IP compliance can help the company win big, say analysts.

Divi's Labs: China+1 sentiment to keep drugmaker on the path of API leadership

Divi's topline and bottomline came in well below the Street estimates, while operating profit margin improved on a sequential basis in the April-June quarter

Brokerages cautious on Divi's Labs, valuation a big worry

Revenue from operations increased 21.2 percent to Rs 1778 crore from Rs 2255 crore last fiscal, the company said.

Divi's Labs Q1 results: Net profit slumps 49% to Rs 356 crore, lags estimate

A high base due to strong COVID-sales contribution from Molnupiravir is expected to weigh on Q1 earnings for Divi's Labs.

Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery

Infosys Ltd, Tech Mahindra Ltd, Wipro Ltd, Indusind Bank, Kotak Mahindra Bank, Bajaj Finance, Bajaj Finserv and RIL are among blue-chip stocks yet to hit their all-time high levels.

Around 4 in 10 Nifty 500 stocks trading 50% below all-time highs amid midcap, and smallcap frenzy

The Nifty is expected that the Nifty will likely continue to trade sideways, as long as it sustains within the range of 19,200 to 19,500, implying a range bound trades unless there is a directional breakout

Hot Stocks | BHEL, Indiabulls Housing Finance, Divis Laboratories can give return up to 18% in short term, here's why?

Kotak Institutional Equities is not convinced with the company’s growth as it has not yet reached its historical asset turnover.

Why Kotak is not sure about Divi’s custom synthesis segment?

Divi's Laboratories Ltd. is a holding company, which engages in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical ingredients. It also provides manufacturing of generic APIs, nutraceutical ingredients, and custom synthesis for big pharma. The company was founded by Murali Krishna Prasad Divi on October 12, 1990 and is headquartered in Hyderabad, India.

Watchers	2,607
52-Wk Low	2,730.00
52-Wk High	3,934.70

Market Cap	988.73B
Volume (M)	241,798.00
52-Wk High	3,934.70
52-Wk Low	2,730.00

DIVISLAB.NSE Divi`s Laboratories Ltd.

About

Feed

News

Sentiment

Fundamentals